Optimizing Lipid Pattern by Adding a Combined Nutraceutical or Pravastatin to Fenofibrate Treatment in Hypertriglyceridemic Subjects: Single Site, Randomized, Open-Label, Post-Market Clinical Investigation

ConclusionIn hypertriglyceridemic patients treated with fenofibrate, the association with a combined lipid lowering nutraceutical seem to be more effective in optimizing residual hypertriglyceridemia than pravastatin 40  mg, while being more tolerable and having similar effect on LDL-C plasma level.
Source: High Blood Pressure and Cardiovascular Prevention - Category: Cardiology Source Type: research